Events in patients with breast cancer and the CHEK2*1100delC mutation (n = 34) compared to those without this mutation (n = 102)
| CHEK2 mutation present (n = 34) | CHEK2 mutation absent (n = 102) | RR | 95% CI | |
|---|---|---|---|---|
| Relative risks (RR) (univariate) and 95% CI are shown. | ||||
| *One patient (without the CHEK2 mutation) had a local recurrence in addition to contralateral breast cancer. Two other patients (one patient with the CHEK2 mutation) had a later diagnosis of distant metastasis. | ||||
| †Including one case with ipsilateral second breast cancer. | ||||
| ‡Other malignancies were: adenocarcinoma of the colon and chondrosarcoma grade I (in patients with the CHEK2 mutation); and fibrous meningioma (in a patient without the CHEK2 mutation). Both patients with a CHEK2 mutation also had a contralateral breast cancer while the patient with the chondrosarcoma was later diagnosed with metastatic disease. | ||||
| §All deaths were related to breast cancer and preceded by distant metastasis. | ||||
| ¶Two of these were synchrone breast cancers (contralateral breast cancer within 1 week). | ||||
| Any event | 16 (47%) | 21 (21%) | 3.86 | 1.91 to 7.78 |
| Contralateral breast cancer* | 7 (21%)¶ | 4 (4%) | 5.74 | 1.67 to 19.65 |
| Local-regional recurrence† | 0 (0%) | 5 (5%) | 0.03 | 0.00 to 284 |
| Distant metastasis | 10 (29%) | 17 (16%) | 2.81 | 1.20 to 6.58 |
| Other malignancy‡ | 1 (3%) | 1 (1%) | 3.19 | 0.20 to 51.09 |
| Death§ | 4 (12%) | 9 (9%) | 1.76 | 0.52 to 5.93 |